10.1021/bm400626w.s001 Tzu-Yu Liu Tzu-Yu Liu Waleed M. Hussein Waleed M. Hussein Zhongfan Jia Zhongfan Jia Zyta M. Ziora Zyta M. Ziora Nigel A. J. McMillan Nigel A. J. McMillan Michael J. Monteiro Michael J. Monteiro Istvan Toth Istvan Toth Mariusz Skwarczynski Mariusz Skwarczynski Self-Adjuvanting Polymer–Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer American Chemical Society 2013 polymer biomacromolecule antigen conjugate peptide protein adjuvant platform Cervical CancerDendrimers pathway papillomaviru HPV vaccine candidate Therapeutic Vaccine Candidates physicochemical properties Polymer e.g Herein TC immunization tumor growth Conjugate 2013-08-12 00:00:00 Journal contribution https://acs.figshare.com/articles/journal_contribution/Self_Adjuvanting_Polymer_Peptide_Conjugates_As_Therapeutic_Vaccine_Candidates_against_Cervical_Cancer/2388541 Dendrimers are structurally well-defined, synthetic polymers with sizes and physicochemical properties often resembling those of biomacromolecules (e.g., proteins). As a result, they are promising candidates for peptide-based vaccine delivery platforms. Herein, we established a synthetic pathway to conjugate a human papillomavirus (HPV) E7 protein-derived peptide antigen to a star-polymer to create a macromolecular vaccine candidate to treat HPV-related cancers. These conjugates were able to reduce tumor growth and eradicate E7-expressing TC-1 tumors in mice after a single immunization, without the help of any external adjuvant.